Tweet
Leading researchers discuss in the latest issue of Multiple Sclerosis Journal:
YES: "The most consistent finding, in almost all of the studies using immune ablation and HSCT, is that the treatment changes the course of MS in the large majority of patients."
http://msj.sagepub.com/content/22/10/1258.full
NO: "Treatment with the monoclonal antibodies natalizumab and in particular alemtuzumab seems to match the efficacy of the most recent series of HSCT using intermediate intensive conditioning with BEAM plus ATG or low intensity conditioning with cyclophosphamide and ATG."
http://msj.sagepub.com/content/22/10/1260.full
COMMENTARY: "Better evidence is needed to provide a more thorough assessment of the benefits versus risks of HSCT compared to already approved, high-potency treatments, as well as guidance regarding the types of patients who would most benefit from it."
http://msj.sagepub.com/content/22/10/1263.full
YES: "The most consistent finding, in almost all of the studies using immune ablation and HSCT, is that the treatment changes the course of MS in the large majority of patients."
http://msj.sagepub.com/content/22/10/1258.full
NO: "Treatment with the monoclonal antibodies natalizumab and in particular alemtuzumab seems to match the efficacy of the most recent series of HSCT using intermediate intensive conditioning with BEAM plus ATG or low intensity conditioning with cyclophosphamide and ATG."
http://msj.sagepub.com/content/22/10/1260.full
COMMENTARY: "Better evidence is needed to provide a more thorough assessment of the benefits versus risks of HSCT compared to already approved, high-potency treatments, as well as guidance regarding the types of patients who would most benefit from it."
http://msj.sagepub.com/content/22/10/1263.full